Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Despite the NSCLC market being largely dominated by Merck &Co’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in around

MSD withdraws Keytruda’s US indication for small cell lung cancer

MSD withdraws Keytruda’s US indication for small cell lung cancer Keytruda failed to meet this requirement in the KEYNOTE-604 trial, as announced in January 2020. ... Keytruda remains a foundational treatment for certain patients with metastatic non-small cell lung cancer.

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US In its new NSCLC setting, Libtayo will take on Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab). ... Keytruda has become the new standard-of-care treatment for newly-diagnosed advanced NSCLC, after first winning approval in

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail NMIBC). A number of immunotherapies are approved for bladder cancer, including Merck &Co/MSD’s Keytruda (pembrolizumab) which became the first checkpoint inhibitor to be approved in the US for NMIBC

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer The overall response rate (ORR) for Keytruda plus Lenvima-treated patients was 71% compared to 36.1% in the Sutent group. ... In this trial, Keytruda plus Lenvima demonstrated superior efficacy benefits compared with Sutent.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics